PMV Pharma Q3 2022 net loss widens to $54M; cash at $258.9M; PC14586 trial ongoing

PMV Pharmaceuticals, Inc.

2022-Q3 EPS reported -$1.18

Net loss for nine months ended Sep 30, 2022: $54.0M vs $39.5M YoY; cash & equivalents $258.9M (Dec 2021: $314.1M).
R&D expenses rose to $37.0M (vs $24.3M) due to PC14586 clinical costs; G&A $18.9M (vs $15.5M).
Enrollment continues in Phase 1/2 PYNNACLE trial of PC14586 for p53 Y220C advanced solid tumors.
Phase 1b combo trial with Merck's KEYTRUDA on track to initiate in Q4 2022.
Appointed Dr. Carol Gallagher to Board; brings 30 years of biotech leadership.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PMV Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-022919

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.